Podcasts about nejm

This week, we discuss a promising step toward a functional cure for chronic hepatitis B, first-line pulsed field ablation for persistent atrial fibrillation, reducing the demand for transfusion in surgery, treatment for rifampicin-resistant tuberculosis, and a decade-long look at CAR T-cell therapy outcomes. We review peanut allergy and discuss a case of a man with leg weakness, pain, and weight loss; Perspectives explore GLP-1 access, air-quality policy, and the human realities of homelessness.

Američtí a izraelští vědci objevili dosud neznámý archív DNA staré nejméně 400 milionů let. Jde o úseky, které rozhodují o tom, které geny budou aktivní a které ne. Takové „vypínače“ v rostlinách zůstaly nejspíš ještě z doby, než se oddělily kvetoucí rostliny od ostatních.Všechny díly podcastu Laboratoř můžete pohodlně poslouchat v mobilní aplikaci mujRozhlas pro Android a iOS nebo na webu mujRozhlas.cz.

Witam Państwa, nazywam się Jarosław Drożdż, pracuję w Centralnym Szpitalu Klinicznym Uniwersytetu Medycznego w Łodzi, skąd nagrywam podcast Kardio Know-How. W tym odcinku omawiam farmakologiczne nowości nefrologiczne.Nerki przez wiele lat mogą chorować bezobjawowo, a ich uszkodzenie bardzo często towarzyszy najważniejszym chorobom serca, takim jak niewydolność serca, nadciśnienie tętnicze czy wady zastawkowe. Dziś coraz większe znaczenie w diagnostyce przewlekłej choroby nerek ma albuminuria oceniana za pomocą wskaźnika UACR, który często wykrywa problem wcześniej niż spadek eGFR; szczegóły omawiałem w odcinku 152 „Albuminuria – praktyczny przewodnik”. W ostatnich latach leczenie nefrologiczne przeszło ogromną zmianę dzięki flozynom, agonistom GLP-1 oraz nowoczesnym antagonistom receptora aldosteronowego. Szczególną uwagę zwróciło opublikowane w NEJM badanie FIND-CKD oceniające finerenon u pacjentów z przewlekłą chorobą nerek bez cukrzycy. Do badania włączono chorych z albuminurią 200–3500 mg/g i eGFR 25–90 ml/min/1,73 m², a obserwacja trwała około trzech lat. Finerenon obniżał ciśnienie tętnicze średnio o 5 mmHg, spowalniał spadek filtracji nerkowej i przyniósł 22% redukcję nerkowych oraz około 40% redukcję sercowo-naczyniowych punktów końcowych. Leczenie było dobrze tolerowane, a ciężka hiperkaliemia występowała bardzo rzadko mimo nieco częstszego wzrostu stężenia potasu niż w grupie placebo. Moim zdaniem badanie wzmacnia pozycję finerenonu, który jako niesteroidowy i selektywny antagonista aldosteronu może okazać się jednym z najważniejszych leków chroniących jednocześnie serce i nerki. Link do publikacji: https://www.nejm.org/doi/full/10.1056/NEJMoa2604625. Szczegółowy TRANSKRYPT do odcinka.Podcast jest przeznaczony wyłącznie dla osób z profesjonalnym wykształceniem medycznym.

Welcome back to the show, everybody! Today, we are diving deep into the intersection of maternal-fetal medicine and cardiology. We're tackling a condition that keeps every OB/GYN, MFM, and cardiologist up at night: Peripartum Cardiomyopathy, or PPCM. And to keep our clinical gears turning, we are framing this discussion squarely through the lens of Society for Maternal-Fetal Medicine (SMFM) Consult Series #73, which focuses on right and left heart failure in pregnancy, alongside the foundational data from ACOG Practice Bulletin #212. PPCM presents fundamentally as acute left heart failure with reduced ejection fraction. Think of the left ventricle as the primary engine pump of the systemic circulation. When it stalls, everything upstream gets backed up. While this was traditionally called IDIOPATHIC, newer data says otherwise. We are going to cover presentation, eval, care and prognosis. So, get your palpitations in check- here we go. 16% OFF TONA ACTIVE WEAR PROMO: https://tonaactive.com/discount/CHAPANOSPINOBG1. SMFM CS 73; 20252. ACOG PB 212; 20193. Arany Z. Peripartum Cardiomyopathy. The NEJM. 2024. 4. Sliwa K, Hilfiker-Kleiner D, Damasceno A, Al Farhan H, Goland S, Johnson MR, Bauersachs J. Peripartum cardiomyopathy. Lancet. 2025 Nov 22;406(10518):2483-2493. doi: 10.1016/S0140-6736(25)01451-5. Epub 2025 Oct 28. PMID: 41173010.

Testosteron fylder mere end nogensinde på sociale medier – men hvad siger evidensen?Anne Møller og Anne Holm er praktiserende læger og seniorforskere. De har gennemgået forskningen og giver dig et overblik. Du får blandt andet svar på, hvornår testosteron bør måles, hvem der kan have gavn af behandling, hvor godt behandlingen virker – og lidt om hvad vi ved om testosteron til kvinder.ReferencerLee et al. Testosterone replacement in men with sexual dysfunction. Cochrane, 2024.Snyder et al. Effects of Testosterone Treatment in Older Men. NEJM, 2016.Lincoff et al. Cardiovascular Safety of Testosterone-Replacement Therapy. NEJM, 2023.Resnick et al. Testosterone Treatment and Cognitive Function in Older Men With Low Testosterone and Age-Associated Memory Impairment. JAMA, 2017.Qaseem et al. Testosterone Treatment in Adult Men With Age-Related Low Testosterone. Ann Intern Med, 2020.Somboonporn et al. Testosterone for Peri- and Postmenopausal Women. Cochrane, 2005.Dansk Endokrinologisk Selskab. Testosteronmangel hos mænd. NBV, 2024.Dansk Selskab for Obstetrik og Gynækologi. Menopausal Hormon Terapi (MHT). DSOG Guideline, 2026Rojas-Zambrano et al. Effects of Testosterone Hormone on the Sexual Aspect of Postmenopausal Women: A Systematic Review. Cureus, 2024.  

This week, we discuss endovascular therapy for post-thrombotic syndrome, new evidence on prehospital blood transfusion strategies in trauma patients, and a trial of cefazolin for Staph. aureus bacteremia. We examine evolving approaches to thyroid cancer and share a case of a man with pancytopenia after heart transplantation. Perspectives explore psychedelic therapy, the convergence of Down syndrome and Alzheimer's disease, and treating addiction.

Marcus Hughes is an assistant professor of psychiatry at the Yale School of Medicine and an attending psychiatrist at Yale New Haven Psychiatric Hospital. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. M. Hughes. Psychedelic Therapies in the United States — Balancing State and Federal Oversight. N Engl J Med 2026;394:2281-2283. Y. Zisman-Ilani and R. Yehuda. Patient-Driven Care in Psychedelic Therapy. N Engl J Med 2026;394:2284-2286.

Fontes do episódio aqui:⁠https://portal.afya.com.br/podcasts/afya-news/17-06-2026Nesta quarta-feira, analisamos uma nova tecnologia na urologia, o papel da anamnese no combate à dependência digital financeira e os dilemas éticos da medicina ambiental. Abordamos os avanços da ureteroscopia flexível assistida por vácuo, uma técnica menos invasiva e altamente eficaz para a eliminação de cálculos renais grandes. Detalhamos o apelo de especialistas publicado no NEJM para que médicos incluam o rastreamento rotineiro de apostas online na anamnese, visando mitigar riscos de depressão e autoextermínio. Por fim, discutimos no Radar um estudo inédito que utilizou a troca terapêutica de plasma para reduzir microplásticos na corrente sanguínea. Afya News. Informação médica confiável e atualizada no seu tempo.

Rozhovor s lektorem angličtiny Jakubem Čáslavou o strachu Čechů z mluvení a o tom, proč dávání kurzů zdarma v praxi nefunguje. V otevřené zpovědi vysvětluje, jak po letech na sociálních sítích došel k vyhoření a proč se rozhodl postovat videa bez toho, aby na sítích sám aktivně trávil čas. Popisuje výuku angličtiny u bojovníka Jiřího Procházky a zmiňuje, jak zápasník řeší souběh titulového zápasu s termínem porodu své partnerky. V rozhovoru dojde také na překlady skrytých významů v textu hitu Despacito nebo na živý kvíz s publikem zaměřený na chytáky v anglické gramatice.

O stavu komárů v Olomouckém kraji, důvodu jejich nízké aktivity i možnost jejich kalamit přiblížil v rozhovoru Libor Mazánek z Krajské hygienické stanice Olomouckého kraje.

Welcome to Episode 8 of our monthly GU Cast Journal Club! Today we focus on two very important papers in localised prostate cancer and metastatic bladder cancer. The landmark 15 year update of the PROTECT trial, published in NEJM in 2023, and the breakthrough EV-301 trial which heralded enfortumab vedotin in progressive metastatic bladder cancer, published in NEJM in 2021.We are delighted to welcome back our GU Cast Journal Club Editors, Dr Carlos Delgado (Mexico City, MEX), and Dr Elena Berg (Munich, GER), along with main GU Cast Hosts, Renu Eapen and Declan Murphy. Links to papers below:1. Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer NEJM 20232. Enfortumab Vedotin in Previously Treated Advanced Urothelial CarcinomaNEJM 2021Even better on our YouTube channelAbout GU Cast Journal Club:Each month, two papers are discussed, each of which are of importance to the GU Oncology community. These may be recent papers, or occasionally we will chose a classic landmark paper in GU Oncology. The objective is to draw attention to important papers in GU Oncology, and critique these in a robust manner. The key target audience is trainees working in Urology, Medical Oncology, Radiation Oncology, Nuclear Medicine, and diagnostic specialties such as Radiology and Pathology. But any of our regular audience are likely to enjoy this Journal Club series.

This week, we present new evidence guiding coronary intervention, a molecular mechanism of inflammatory bowel disease, and gene therapy for a recessive disease. We review antidotes for anticoagulation reversal and discuss a case of hypertension in an adolescent patient. Perspectives examine cholera control, gambling-related harms, and race-based prescribing, alongside a reflection on medicine, motherhood, and what clinicians carry with them.

Edward Ryan is the director of global infectious diseases at Massachusetts General Hospital. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. E.T. Ryan, F. Qadri, and J.A. Lynch. Global Cholera-Control Efforts — Progress and Remaining Challenges. N Engl J Med 2026;394:2177-2180.

Microplastics and Stroke Risk: What a Landmark 2024 Study Found Inside Human Arteries In 2024, a team of Italian researchers published a study in the New England Journal of Medicine that stopped the cardiovascular science community in its tracks. They found microplastics, tiny synthetic fragments embedded inside the carotid artery plaque of more than half the patients they examined. And the patients who had them faced more than four and a half times the risk of a serious cardiovascular event compared to those who didn’t. This isn’t a distant, theoretical risk. These are living people who had already been identified as having carotid artery disease, and plastics were found inside their arterial walls. For stroke survivors and those at elevated risk of stroke, this study raises important questions that the medical system has not yet caught up with. What the Research Found The study by Marfella et al., published in the New England Journal of Medicine (2024), enrolled 304 patients who were undergoing carotid endarterectomy, a surgical procedure to remove plaque from the carotid arteries. Researchers analysed the excised plaque for the presence of microplastics and nanoplastics. Their findings: 58% of patients had detectable levels of polyethylene, polyvinyl chloride (PVC), or polystyrene in their arterial plaque. This was not contamination from the surgical procedure; it was already there. Over a 34-month follow-up period, patients with microplastics in their plaque had a 4.53 times higher risk of a combined endpoint: non-fatal myocardial infarction, non-fatal stroke, or death from any cause. Inflammatory markers were significantly elevated in the microplastics-positive group. IL-18 and TNF-alpha proteins associated with systemic vascular inflammation were markedly higher in plaque samples that contained plastics. This suggests the mechanism is not simply physical obstruction, but an inflammatory cascade triggered by the presence of synthetic material in arterial tissue. What This Means for Stroke Survivors The carotid arteries are the primary conduits supplying oxygenated blood to the brain. Plaque accumulation in these vessels is one of the leading causes of ischaemic stroke, and carotid artery disease is a condition many stroke survivors are already living with. “The patients with microplastics in their plaque had a 4.53 times higher risk of stroke, heart attack, or death over the 34-month follow-up. That’s not a marginal finding. That’s a signal the research community needed to take seriously.” The NEJM study doesn’t yet tell us whether removing microplastic exposure after the fact reduces risk. It doesn’t confirm that healthy individuals with no existing carotid disease are accumulating plastics at the same rate. And it cannot tell us which plastic sources are most responsible because we’re exposed to microplastics through drinking water, food packaging, air, and a dozen other vectors simultaneously. But what it does tell us clearly and with high statistical significance is that microplastics in arterial plaque are associated with dramatically worse cardiovascular outcomes. What the Research Does Not Yet Tell Us Science at the frontier moves in one direction at a time. This study establishes association, not causation. It cannot yet answer: Whether people without existing carotid disease are accumulating microplastics at comparable rates. Whether reducing exposure actively reverses or slows plaque-associated risk. Which types of microplastics are most biologically harmful? Whether there will be a clinical screening tool for this in the near future. These are the questions the next generation of research will need to answer. In the meantime, it’s reasonable to act on what we do know. Practical Steps to Reduce Exposure No clinical screening currently exists for microplastics in arterial plaque. There is no blood test, no imaging, no biomarker that your GP can order today. What you can do is reduce your ongoing exposure, particularly through food and water contact with plastics. Evidence-informed steps worth discussing with your treating team: Use glass, stainless steel, or ceramic containers rather than plastic for food and drink storage. Avoid microwaving food in plastic containers; heat accelerates the leaching of plastic particles. Filter your drinking water; some filters (carbon block and reverse osmosis) reduce microplastic levels significantly. Reduce consumption of highly processed foods in plastic packaging. Bring this study to your vascular neurologist, cardiologist, or GP and ask whether it’s relevant to your personal risk profile. This is not a recommendation to take a supplement or start a treatment. It’s an invitation to have an informed conversation with the people responsible for your care using the best available evidence. If you found this useful, my book walks through the science of stroke recovery in the same evidence-first, no-hype way. Find it at recoveryafterstroke.com/book. Want to go deeper and support the channel? Join the community at patreon.com/recoveryafterstroke. The post Plastics in Your Arteries: The Stroke Risk Study You Must Know appeared first on Recovery After Stroke.

This week on the Osterholm Update, Dr. Michael Osterholm and Chris Dall focus on the developing Ebola outbreak in the Democratic Republic of Congo, discussing the U.S. response, whether transmission can be airborne, and addressing travel concerns to Africa. We'll also bring you the latest on the hantavirus outbreak, review a long-awaited report from the FDA on pediatric deaths linked to COVID vaccines, and provide updates on measles and other respiratory viruses. Plus, a Public Health History segment highlighting the first EMS service in the U.S.  Links:‘Among the things he feared most was death': the doctors and nurses dying on the Ebola frontline (The Guardian) Inside the Ebola Epicenter, the Virus Rages With Little to Stop It (The New York Times) Opinion: This Ebola outbreak is a test the world doesn't have to fail (The Washington Post)People with Ebola pose little risk to public in US, experts say (CIDRAP) Transmission of Ebola Viruses: What We Know and What We Do Not Know (ASM Journals) Public Health Alerts: Andes Hantavirus Outbreak on a Cruise Ship, 2026 (NEJM and CIDRAP)  Resources for vaccine and public health advocacy: Voices for Vaccines Families Fighting Flu Vaccinate Your Family Shot@Life Medical Reserve Corps Learn more about the Vaccine Integrity Project MORE EPISODES       SUPPORT THIS PODCAST   Music: "Beauty Flow" Kevin MacLeod (incompetech.com)Licensed under Creative Commons: By Attribution 4.0 License

„Být v domácím prostředí a v klidu se tam léčit, je určitě nejlepší a nejpohodlnější,“ popisuje jeden z bonusů primář oddělení Jednodenní péče šternberské nemocnice Peter Gálóczy.

Send us Fan MailPost-thrombotic syndrome (PTS) affects up to half of patients following deep vein thrombosis and can significantly impair quality of life. Yet treatment options have historically been limited.In this episode of CLOT Conversations, David Airdrie and Dr. Jameel Abdulrehman speak with Dr. Susan Kahn about the recently published C-TRACT trial in The New England Journal of Medicine.The trial evaluated whether endovascular therapy, including iliac vein stenting, could improve outcomes for patients with moderate-to-severe post-thrombotic syndrome and iliac vein obstruction.Dr. Kahn discusses the rationale behind the study, key findings related to symptom burden and quality of life, the increased bleeding risk observed with intervention, practical patient selection considerations, and the unanswered questions that remain regarding long-term management after venous stenting.This episode provides clinicians with practical insights into one of the most important recent studies in the management of post-thrombotic syndrome.Reference:Vedantham S, Kahn SR, Marston WA, Weinberg I, Sista AK, Magnuson EA, Cohen DJ, Wasan SM, Razavi MK, Goldhaber SZ, Sanfilippo KM. Endovascular Therapy for Post-Thrombotic Syndrome—A Randomized Trial. New England Journal of Medicine. 2026 Apr 13.https://www.nejm.org/doi/abs/10.1056/NEJMoa2519001Support the showhttps://thrombosiscanada.caRegister today for our upcoming conference on November 7, 2026 in Montreal at https://thrombosiscanada.ca/2026ConferenceTake a look at our healthcare professional and patient resources, videos and publications on thrombosis from the expert members of Thrombosis Canada

This week, we discuss left atrial appendage closure for atrial fibrillation, oxygen strategies in respiratory failure, an all-oral treatment for acute myeloid leukemia, CAR T-cell therapy enabling kidney transplantation, and a case of a neuroepithelial tumor that developed after gene therapy. We review childhood vaccine hesitancy, follow a complex diagnostic case, and examine Perspectives on corporatization in medicine, famine and war, and the future of health care systems.

Loren Adler is a fellow and the associate director at the Center on Health Policy at the Brookings Institution. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. L. Adler. Regulating Corporate Control in the U.S. Health Care System. N Engl J Med 2026;394:2073-2076.

Send us a Text Message (please include your email so we can respond!)Episode 93! In this episode we go over TOWAR or "Prehospital Resuscitation with Type O Whole Blood for Trauma and Hemorrhage" by Sperry et all published in NEJM and "Remote Multicomponent Rehabilitation in Intensive Care Unit Survivors" published by O'Neill et al in JAMA both in May 2026 and presented at the ATS International Conference! Then we talk a little bit about some current events with Hantavirus and sepsis that has hit the news cyclesTOWAR (NEJM): https://www.nejm.org/doi/full/10.1056/NEJMoa2602167iRehab (JAMA): https://jamanetwork.com/journals/jama/fullarticle/2849320If you enjoy the show be sure to like and subscribe, leave that 5 star review! Be sure to follow us on the social @icucast for the associated figures, comments, and other content not available in the audio format! Email us at icuedandtoddcast@gmail.com with any questions or suggestions! Thank you Mike Gannon for the intro and exit music! 

The NACE Journal Club with Dr. Neil Skolnik, provides review and analysis of recently published journal articles important to the practice of primary care medicine. In this episode Dr. Skolnik and guests review the following publications:1. Orforglipron for maintenance of body weight reduction  - Nature Medicine2026. Discussion by:Guest:Joe Gonella, MD Resident - Abington Family Medicine Residency Program Jefferson Health2. Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN) Lancet 2026.  Discussion by: Guest:Neil Skolnik, MDProfessor of Family and Community MedicineSidney  Kimmel  Medical College Thomas Jefferson UniversityAssociate Director - Family Medicine Residency ProgramJefferson Health – Abington3. Survival and Recurrence with GLP-1 Receptor Agonists in Breast Cancer" – JAMA Network Open Discussion by:Guest:Neil Skolnik, MDProfessor of Family and Community MedicineSidney  Kimmel  Medical College Thomas Jefferson UniversityAssociate Director - Family Medicine Residency ProgramJefferson Health – Abington4. In Vivo Base Editing of PCSK9 with VERVE-102 for Hypercholesterolemia.   NEJM 2026 Discussion by:Guest:Alex Sauer, MD Resident - Abington Family Medicine Residency ProgramJefferson HealthMedical Director and Host, Neil Skolnik, MD, is an academic family physician who sees patients and teaches residents and medical students as professor of Family and Community Medicine at the Sidney Kimmel Medical College, Thomas Jefferson University and Associate Director, Family Medicine Residency Program at Abington Jefferson Health in Pennsylvania. Dr. Skolnik graduated from Emory University School of Medicine in Atlanta, Georgia, and did his residency training at Thomas Jefferson University Hospital in Philadelphia, PA. This Podcast Episode does not offer CME/CE Credit. Please visit  http://naceonline.com to engage in more live and on demand CME/CE content.

Breaking News podcast just after the long-awaited PROTEUS trial reads out at the ASCO Plenary in Chicago! Plus a simultaneous NEJM paper! Huge day for prostate cancer surgery. Declan and Renu are joined by lead author Dr Mary-Ellen Taplin (Dana Farber Cancer Institute & Harvard University), to tell us about her decades long journey to this huge moment today. PROTEUS is a huge (2,100 men) phase III RCT of men undergoing radical prostatectomy for high-risk prostate cancer, randomised to receive peri-operative ADT + placebo, or ADT plus apalutamide. Mary-Ellen talks to us about the top-line results, and we consider whether this is truly a practice-changing study. Declan also had the honour of being the Discussant at teh ASCO Plenary so he is well placed to give his opinion. Your usual hosts are Declan Murphy & Renu Eapen. Even better on our YouTube channel This is a Themed Podcast supported by our Gold Partner, Johnson & Johnson.Links:PROTEUS NEJM paper

We sit down with Joshua Oommen to get nerdy about clinical reasoning, FDA standards, and why “good evidence” is harder to define than most of us admit. We challenge the reflex to trust p-values and meta-analyses, then test our instincts against real OBGYN examples where the literature has whiplashed practice. • why the podcast is called Thinking About OBGYN and how clinical reasoning shapes our work • the NEJM proposal to make one pivotal trial the FDA default and what “confirmatory evidence” might mean • medical reversal, surrogate endpoints, and how trust erodes when practice changes late • why Bayesian thinking fits how clinicians interpret tests, trials, and prior beliefs • how meta-analyses fail through small study effects, publication bias, p-hacking, and heterogeneity • the amnioinfusion comeback as a case study in applicability and overconfident conclusions Be sure to check out thinking about obgyn.com for more information and be sure to follow us on Instagram. 0:00 Welcome And Today's Big Question3:48 Why “Thinking About OBGYN” Exists11:54 The NEJM Push For One Trial16:38 Medical Reversal And Trust Problems24:43 AI Proteins And CRISPR Pressure Tests32:33 Bayes Thinking Beyond P Values36:43 Why Meta-Analyses Often Mislead41:08 Bias And Heterogeneity Red Flags46:24 Amnioinfusion And A Meta-Analysis Comeback1:02:29 Final Warnings And How To LearnFollow us on Instagram @thinkingaboutobgyn.

Seu paciente chega no consultório com um vidro de ômega-3 importado e te olha esperando confirmação: "é bom pro coração, né, doutor?" Durante décadas, a resposta foi automática. Hoje, ela precisa de mais cuidado, e de evidência.Nesse episódio, Mateus Prata e Raphael Rossi mergulham de cabeça na história do ômega-3 e risco cardiovascular: da expedição dos anos 1970 à Groenlândia até o PISCES, publicado no NEJM em 2025. Um episódio que vai te fazer repensar o que você diz (e prescreve) no consultório.O que você vai aprender:

This week, we present new research guiding treatment of pulmonary embolism, early progress in cardiac regeneration with engineered heart tissue, and treatments for gastroesophageal cancer and Chiari malformation. We review leishmaniasis and follow a revealing neurologic case. Perspectives discuss nutrition policy, tickborne illness, structural competence in medicine, and the arrival of closure.

Deirdre Tobias is an associate professor in the Department of Nutrition at the Harvard T.H. Chan School of Public Health and Brigham and Women's Hospital. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. D.K. Tobias and F.B. Hu. The 2025–2030 Dietary Guidelines for Americans — Progress, Pitfalls, and the Path Forward. N Engl J Med 2026;394:1969-1971.

Eric Rubin is the Editor-in-Chief of the Journal. Lindsey Baden is a Deputy Editor of the Journal. Angela Hewlett is Director of the Nebraska Biocontainment Unit. Steven Kornfeld is a physician who was a passenger on the MV Hondius. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. E.J. Rubin and Others. NEJM Outbreaks Update — Andes Hantavirus. N Engl J Med. DOI: 10.1056/NEJMe2505379.

This week we review a landmark paper from the NEJM by the SCOUT-HCM study group assessing the impact of mavacamten on HCM in the adolescent patient. How does this agent work and what impact did it have on the LVOT gradients in obstructed HCM teens? Does this agent affect other biomarkers associated with more obstruction in this setting? Who is a good potential candidate for the use of this agent? Why must the EF be carefully monitored while using this agent? Dr. Joseph Rossano, Professor of Pediatrics at The University of Pennsylvania and the chief of pediatric cardiology at The Children's Hospital of Philadelphia joins the podcast to discuss this groundbreaking work.doi: 10.1056/NEJMoa2601103

Five longevity beliefs that millions have followed for decades have just been overturned by the latest research. Some of these will surprise you.In this explainer, Robert Lufkin MD walks through five of the most widely believed longevity myths — and what the most recent science actually says about each one. From genetics and middle age to antioxidants, alcohol, and caloric restriction, the evidence has shifted dramatically.CHAPTERS:00:00 — Introduction00:32 — Myth 1: Your Genes Determine How Long You Live01:51 — Myth 2: It's Too Late to Change After Middle Age03:24 — Myth 3: Antioxidant Supplements Prevent Disease05:22 — Myth 4: Moderate Alcohol Is Good for You07:04 — Myth 5: Caloric Restriction Is King08:50 — The Real Framework: Quality Beats Quantity09:18 — Final TakeawayKEY TAKEAWAYS:• Genetics accounts for at most 25–50% of how long you live• Quitting smoking before 40 eliminates ~90% of excess mortality risk• Antioxidant supplements have no benefit and may increase mortality• The protective J-curve for moderate alcohol disappears once you correct for the "sick quitter" effect• Caloric restriction's primate magic was rescuing animals from a high-sugar control diet• Diet quality matters more than diet quantitySTUDIES & SOURCES MENTIONED:• Herskind et al., Human Genetics 1996 — 2,872 Danish twin pairs heritability of longevity• Jha et al., NEJM 2013 — 21st-century smoking cessation and life expectancy• Saint-Maurice et al., JAMA Network Open 2019 — Adult life-course physical activity and mortality• Bjelakovic et al., Cochrane 2012 — Antioxidant supplements for prevention of mortality• Zhao et al., JAMA Network Open 2023 — Daily alcohol intake and all-cause mortality meta-analysis• Mattison et al., Nature Communications 2017 — Caloric restriction in rhesus monkeys (NIA / Wisconsin reconciliation)⭐ Enjoying the show? Please leave a 5-star review on Apple Podcasts — it takes 30 seconds and helps more people discover the science of health and longevity. Thank you!New episodes every Tuesday & Thursday. Subscribe so you don't miss one.Continue this conversation on Substack: https://robertlufkinmd.substack.comLies I Taught In Medical School — Free sample chapter: https://www.robertlufkinmd.com/lies/Web: https://www.robertlufkinmd.comYouTube: https://www.youtube.com/robertlufkinmdX: https://x.com/robertlufkinmdInstagram: https://www.instagram.com/robertlufkinmd/TikTok: https://www.tiktok.com/@robertlufkinLinkedIn: https://www.linkedin.com/in/robertlufkinmd/

This week, we present a promising new therapy for dermatomyositis, evolving approaches to stroke care, the prevention of Covid-19 after household exposure, and new treatments for kidney disease. We review inflammatory myopathies and follow a complex case of multisystem illness. Perspectives discuss AI and uncertainty in clinical care, health equity, the forces shaping affordability in health care, and on unpacking the ordinary.

Raja-Elie Abdulnour is the Chief Clinical Innovation Officer at NEJM Group and an associate physician in the Pulmonary and Critical Care Medicine Division at Brigham and Women's Hospital. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. A. Sikora, L.A. Celi, and R.-E.E. Abdulnour. Can AI Say “I Don't Know”? N Engl J Med 2026;394:1873-1875.

This week, we present research on high-risk coronary intervention strategies, targeted therapy for pancreatic cancer, an mRNA influenza vaccine, and treatments for severe scabies and sickle cell disease. We review cerebral amyloid angiopathy and follow a complex case of a disseminated infection. Perspectives address the impact of corporate medicine on medical training and drug pricing policy.

Jatin Vyas is a professor of medicine and associate dean for academic innovation at the Columbia University Vagelos College of Physicians and Surgeons. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. J.M. Vyas. From Mission to Margin in Academic Medicine — The Impact of Corporate Medicine on Medical Training. N Engl J Med 2026;394:1769-1772.

Can AI think like a physician?

A quiet revolution in tuberculosis diagnostics is here.

The NACE Journal Club with Dr. Neil Skolnik, provides review and analysis of recently published journal articles important to the practice of primary care medicine. In this episode Dr. Skolnik and guests review the following publications:1. Evolocumab to Reduce First Major Cardiovascular Events in Patients Without Known Significant Atherosclerosis and With Diabetes Results From the VESALIUS-CV Trial. JAMA 2026. Discussion by:Guest:Jessica Stieritz, MDResident - Abington Family Medicine Residency Program Jefferson Health2. A treat-to-target strategy versus symptom-driven management of gout in the Netherlands (GO TEST Overture): a multicentre, open-label, pragmatic, superiority, randomized controlled trial. Lancet Rheumatology 2026. Discussion by:Guest:Neil Skolnik, MDProfessor of Family and Community MedicineSidney  Kimmel  Medical College Thomas Jefferson UniversityAssociate Director - Family Medicine Residency ProgramJefferson Health – Abington3. Oral Nirmatrelvir–Ritonavir for Covid-19 in Higher-Risk Outpatients. NEJM 2026 Discussion by: Guest:Steven Leonard, MD Resident - Abington Family Medicine Residency Program Jefferson HealthMedical Director and Host, Neil Skolnik, MD, is an academic family physician who sees patients and teaches residents and medical students as professor of Family and Community Medicine at the Sidney Kimmel Medical College, Thomas Jefferson University and Associate Director, Family Medicine Residency Program at Abington Jefferson Health in Pennsylvania. Dr. Skolnik graduated from Emory University School of Medicine in Atlanta, Georgia, and did his residency training at Thomas Jefferson University Hospital in Philadelphia, PA. This Podcast Episode does not offer CME/CE Credit. Please visit  http://naceonline.com to engage in more live and on demand CME/CE content.

This week, we feature advances in targeted therapy for HER2-mutant lung cancer, interventions to reduce maternal infection, an emerging treatment for hemophilia A, and a new diagnostic test for tuberculosis. We review Barrett's esophagus and follow a case of systemic illness with kidney failure. Perspectives address GLP-1 drugs and eating disorders, directed blood donation, generic drug safety, and an in-flight medical emergency.

Amanda Banks is a consultant and a physician at the Corporal Michael J. Crescenz VA Medical Center. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. A. Banks. GLP-1 Receptor Agonists and Eating Disorders — Cause for Concern. N Engl J Med 2026;394:1665-1667.

This week, we explore new strategies for blood-pressure control after intracerebral hemorrhage, Covid-19 treatment in higher-risk patients, hormonal therapy for prostate cancer, and anesthesia for tracheal intubation. We review spinal epidural abscess and follow a case of progressive weakness and liver lesions. We examine advances in tRNA research, and Perspectives discuss the use AI in prescribing, pediatric drug research, the impact of pharmaceutical mergers, and the goals of care.

Sara Gerke is an associate professor of law and at the European Union Center at the University of Illinois Urbana-Champaign. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. S. Gerke, R.B. Parikh, and I.G. Cohen. Utah's Prescription-Renewal Pilot Program — Autonomous AI Managing Patient Care. N Engl J Med 2026;394:1561-1563.

A thoughtful, practice-shaping study in NEJM explores a long-standing clinical dilemma: can we truly move the needle in post-thrombotic syndrome?   The C-TRACT trial shows that endovascular therapy (iliac-vein stenting) significantly improves symptom burden and quality of life in patients with moderate–severe disease—measured rigorously using VCSS, VEINES-QOL, and SF-36. The magnitude of benefit is clinically meaningful.   But every intervention casts a shadow.  

Yes we have covered antenatal corticosteroids in the late preterm interval on several episodes in the past- it's DEJA VU! However, there is new data in the American Journal of Perinatology (April 2026 ) that is helpful for us as clinicians as we do “shared decision making” with patients in offering betamethasone in the late preterm interval. Listen in for details.1. Zigron R, Rotem R, Erlichman I, Rottenstreich M, Rosenbloom JI, Porat S, Rottenstreich A. Factors associated with the development of neonatal hypoglycemia after antenatal corticosteroid administration: It's all about timing. Int J Gynaecol Obstet. 2022 Aug;158(2):385-389. doi: 10.1002/ijgo.13975. Epub 2021 Oct 30. PMID: 34625970.2. Asirwatham A, Loke R, Rose S, Ho J, Leung K, Leftwich HK. Neonatal Hypoglycemia after Antenatal Late Preterm Steroids. Am J Perinatol. 2026 Apr;43(5):616-620. doi: 10.1055/a-2663-5798. Epub 2025 Aug 4. PMID: 40759170.3. ALPS Trial. NEJM. Published April 7, 2016;374:1311-1320

This week, we present new research on stroke prevention, Kawasaki disease, ICU infection strategies, and immune thrombocytopenia. We review hormone therapy and thrombotic risk. A case highlights an evolving diagnosis of severe fatigue and sleep disturbance. Perspectives explore nursing workforce policy, the role of nurse scientists in rebuilding trust, and the health consequences of environmental rollbacks.

Amy Stimpfel is an assistant professor at the New York University Rory Meyers College of Nursing. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. A.W. Stimpfel and M. Djukic. Using Data to Inform Decision Making — Borrowing Limits for Graduate Nursing Students. N Engl J Med 2026;394:1457-1459. P. Joseph and Others. Nurse Scientists as Trusted Voices in Health Communication. N Engl J Med 2026;394:1459-1461.

In this week's episode, we continue our journey through the relapsed/refractory myeloma space, with a focus on the role of bispecific T-cell engagers. Another incredibly important conversation that is so important in the current treatment landscape and one that you don't want to miss.If you haven't done so already, be sure to check out our CAR T episode.Content:- What are bispecific T-cell engagers? - How are they different than CAR T? - A discussion of the pivotal MajesTEC-3 trial (NEJM 2025) - What are key side effects?- How to sequence CAR T vs. bispecific T-cell engagers? ** This episode is sponsored by The Lymphoma, Leukemia and Myeloma Congress! To learn more and register for the meeting, visit llmcongress.com/podcast! Be sure to use our special TFOC code TFOC40 to save 40% off registration. ** Want to review the show notes for this episode and others? Check out our website. Love what you hear? Tell a friend and leave a review on our podcast streaming platforms!Twitter: @TheFellowOnCallInstagram: @TheFellowOnCallListen in on: Apple Podcast, Spotify, and Youtube

This week, we present new research on intensive LDL cholesterol targets, team-based strategies to improve blood pressure control, emerging therapies for immune and oncologic diseases, and a next-generation yellow fever vaccine. We review celiac disease and follow a compelling case of post-procedural complications. Perspectives explore health disparities and efforts to strengthen care in vulnerable communities.